Sep 19, 2023 2 minute read

Elekta is expanding an existing strategic partnership with Novartis to support patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (mBC), receiving ribociclib in a combination therapy. The collaboration is part of the previously announced partnership, where Elekta and Novartis are developing and providing personalized digital patient monitoring and support on the Kaiku Health platform, to support cancer patients during their therapies.

During this collaboration, Novartis and Elekta have developed a therapy-specific digital patient monitoring module for patients with mBC receiving ribociclib in combination with endocrine therapy. Initially the module will be implemented at selected sites in Italy and Canada, following the patients' symptoms during their therapies, as well as patient-reported outcomes (PROs), offering personalized self-management instructions based on the reported symptoms and educational materials relevant for their condition and treatment, to support physical and emotional well-being. Additionally, the module provides a messaging feature, connecting the patient and their care team in real time. This enables the physician to receive alerts for specific symptoms or PRO results.

Collaborating in breast cancer care marks an important milestone in expanding Novartis and Elekta’s existing partnership to new cancer indications, after the successful initial collaboration in developing digital patient monitoring for melanoma patients.

“We share an ambition to provide support for an increasing number of cancer indications, as there is a strong shared vision of digital support tools being able to help patients during their cancer care journey and engage them better to their treatment, as well as ultimately drive improved outcomes” says Reetta Arokoski , Head of Life Sciences & Data Partnerships at Elekta.